Adding Veliparib Extends Time Without Disease Progression in Metastatic Ovarian Cancer, Phase 3 Trial Finds

Adding Veliparib Extends Time Without Disease Progression in Metastatic Ovarian Cancer, Phase 3 Trial Finds
Using veliparib in combination with chemotherapy as first-line and then maintenance therapy post-surgery significantly extended the time without disease progression in women with newly diagnosed metastatic high-grade serous (HGS) ovarian cancer, according to Phase 3 trial results. The research was presented in the session, “VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube or primary peritoneal origin HGSC,” at the 2019 European Society for Medical Oncology (ESMO) Congress and published in the New England Journal of Medicine. Veliparib is an investigational PARP enzyme inhibitor developed by AbbVie. It is designed to prevent cancer cells from repairing DNA errors and thereby cause their death. The international, AbbVie-sponsored VELIA Phase 3 trial (NCT02470585) assessed the p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *